Viridian Therapeutics Stock (NASDAQ:VRDN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.28

52W Range

$11.40 - $25.39

50D Avg

$20.91

200D Avg

$16.98

Market Cap

$1.74B

Avg Vol (3M)

$1.39M

Beta

1.09

Div Yield

-

VRDN Company Profile


Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

94

IPO Date

Jun 18, 2014

Website

VRDN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Collaboration Revenue$300.00K$1.80M$2.96M
Grant---

Fiscal year ends in Dec 23 | Currency in USD

VRDN Financial Summary


Dec 23Dec 22Dec 21
Revenue$314.00K$1.77M$2.96M
Operating Income$-254.45M$-134.30M$-79.73M
Net Income$-237.73M$-125.44M$-79.42M
EBITDA$-254.45M$-129.39M$-79.29M
Basic EPS$-0.01$-3.91$-6.66
Diluted EPS$-0.01$-3.91$-6.66

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 08, 24 | 12:00 AM
Q1 23May 13, 23 | 6:02 PM
Q4 22Mar 08, 23 | 12:00 AM

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
NUVLNuvalent, Inc.
RVMDRevolution Medicines, Inc. Warrant
MRUSMerus N.V.
BPMCBlueprint Medicines Corporation
CERECerevel Therapeutics Holdings, Inc.
REPLReplimune Group, Inc.
SNDXSyndax Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
ACLXArcellx, Inc.
GPCRStructure Therapeutics Inc.
ETNB89bio, Inc.
PCVXVaxcyte, Inc.
PTGXProtagonist Therapeutics, Inc.
CYTKCytokinetics, Incorporated
KURAKura Oncology, Inc.